Healthcare Industry News: Mylan Laboratories
News Release - May 30, 2007
Mylan Announces Final FDA Approval for Fluoxetine Capsules USP, 40 mgPITTSBURGH, May 30 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules USP, 40 mg.
Fluoxetine Capsules are the generic version of Eli Lilly and Company's ProzacŪ Capsules. Fluoxetine Capsules had U.S. sales of approximately $118 million for the 12 months ending March 31, 2007, for the 40 mg strength.
This product will be shipped immediately.
Mylan previously received approval and is currently marketing the 10 mg and 20 mg strength of fluoxetine capsules.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.
For more information about Mylan, please visit www.mylan.com.
Source: Mylan Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.